<DOC>
	<DOCNO>NCT00003222</DOCNO>
	<brief_summary>RATIONALE : Vaccines make melanoma cell may make body build immune response kill tumor cell . Colony-stimulating factor GM-CSF may increase number immune cell find bone marrow peripheral blood . Interleukin-2 may stimulate person 's white blood cell kill melanoma cell . Combining vaccine therapy GM-CSF interleukin-2 may kill tumor cell . PURPOSE : Phase II trial study effectiveness vaccine make melanoma cell without GM-CSF follow interleukin-2 treating patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Plus Interleukin-2 Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effectiveness vaccination synthetic melanoma peptide pulse autologous dendritic cell versus vaccination synthetic melanoma peptide plus sargramostim ( GM-CSF ) decrease tumor burden patient high risk melanoma ( pulse autologous dendritic cell arm close 1/8/2001 ) . II . Determine whether regimens result increase tumor specific immune response measure vitro vivo . III . Determine whether regimens stimulate T-cell response patient . OUTLINE : This open label study . Patients include treatment arm II ( arm I close 1/8/2001 ) : Arm I : Patients undergo leukapheresis collect dendritic cell . Patients receive mixture synthetic melanoma peptide ( gp100 antigen , tyrosinase , tetanus peptide ) pulse autologous dendritic cell IV subcutaneously ( SC ) . Arm II : Patients receive mixture synthetic melanoma peptide ( gp100 antigen , tyrosinase , tetanus peptide ) sargramostim ( GM-CSF ) emulsify Montanide ISA-51 SC intradermally . Patients receive vaccination week 0 , 1 , 2 , 4 , 5 , 6 total 6 dos interleukin-2 SC daily day 7-49 . Patients receive 3 additional vaccination different site involve tumor concurrently first 3 vaccination . Patients evaluate 8 week , 12 week , 6 month , 12 month , 24 month . PROJECTED ACCRUAL : A total 27-54 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage III IV melanoma gp100 positive tumor cell and/or tyrosinase positive tumor cell HLA type A1 , A2 , A3 Measurable disease May 3 brain metastasis less 2 cm diameter asymptomatic , mass effect treat successfully surgical excision gamma knife radiation therapy PATIENT CHARACTERISTICS : Age : 18 79 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL Hepatic : Bilirubin great 2.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class II , III , IV heart disease Other : No know suspect allergy component vaccine No medical condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 month since prior growth factor At least 3 month since prior agent putative immunomodulating activity ( except nonsteroidal antiinflammatory agent ) At least 1 year since prior melanoma vaccination Chemotherapy : At least 3 month since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 3 month since prior corticosteroid No concurrent corticosteroid Radiotherapy : At least 3 month since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 3 month since prior investigational drug therapy At least 3 month since prior allergy desensitization injection At least 14 day since completion acute treatment serious infection No concurrent allergy desensitization injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>